Skip to content

Rees Adomako, D.O

NPI 1063891042ActiveIndividual· Internal Medicine, Cardiovascular Disease· Omaha, NE

Internal Medicine, Cardiovascular Disease (D.O) in Omaha, Nebraska, licensed in NE, with an NPI issued in May 2015. Part D covered 130 prescriptions written in 2024, 86% of them generic. Astrazeneca Pharmaceuticals LP was the largest of 5 companies reporting payments in 2025, $726.77 in all, mostly food and beverage.

Overview

NPI1063891042
StatusActive
Entity typeIndividual
CredentialD.O
Sole proprietorNo
NPI issuedMay 25, 2015
Last updated in NPPESAug 7, 2026
Certified by providerAug 7, 2026

Specialties and licenses

TaxonomyCodeLicenseState
Internal Medicine, Cardiovascular Disease Primary207RC0000X2981NE

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Oct 9, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 10, 2026No match—
New York OMIG · Nov 10, 2026No match—
Ohio Medicaid · Nov 10, 2026No match—
Pennsylvania Medicheck · Nov 10, 2026No match—
Washington HCA · Nov 10, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Enrolled Practitioner - Cardiovascular Disease (Cardiology) (IA); Practitioner - Cardiovascular Disease (Cardiology) (NE)

Part D prescriptions in 2024

Prescriptions (claims)130 · 284 30-day fills
Patients54
Total drug cost$17,154
Generic share86% of claims

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$726.77 · 12 payments from 5 companies
  • 2024$1,029 · 9 payments from 6 companies

Top paying companies in 2025

What the 2025 payments were for

  • Food and Beverage$726.77 · 12 payments

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other Internal Medicine, Cardiovascular Disease providers in Omaha

All Internal Medicine, Cardiovascular Disease providers in Nebraska →